Akari Therapeutics Plc (AKTX) Cash Flow Statement
Akari Therapeutics Plc (AKTX) generated -$10.8M of operating cash flow over the twelve months to 2026-06-30, spent -$191000 on capital expenditure and had free cash flow of -$10.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AKTXAkari Therapeutics PlcFollow AKTX — free
—
Price chart with a free account
- Market cap
- 640.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2006 Dec 06 | FY2007 Dec 07 | FY2008 Dec 08 | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | — | — | -2.1 | -5.5 | -1.5 | -5.0 | -24.6 | -31.6 | -22.8 | -12.9 | -17.0 | -18.8 | -21.5 | -16.4 | -12.6 | -10.6 | -10.8 | |
| Capital expenditure | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | — | — | — | — | 0.0 | 0.0 | 0.2 | |
| Free cash flow | — | — | — | — | — | — | -2.1 | -5.5 | -1.5 | -5.0 | -24.7 | -31.6 | -22.8 | -12.9 | — | — | — | — | -12.6 | -10.6 | -10.6 | |
| Stock-based compensation | 0.1 | 0.4 | 0.2 | 0.1 | 0.0 | 0.1 | 0.5 | 0.1 | 0.0 | 1.0 | 3.9 | 2.7 | 1.6 | 1.0 | 0.3 | 0.3 | 0.7 | 1.2 | 2.2 | 2.9 | — |
USD millions · SEC XBRL
Akari Therapeutics Plc — questions
- What is Akari Therapeutics Plc's operating cash flow?
- -$10.8M over the twelve months to 2026-06-30.
- How much does Akari Therapeutics Plc spend on capital expenditure?
- -$191000 over the twelve months to 2026-06-30.
- What is Akari Therapeutics Plc's free cash flow?
- -$10.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Akari Therapeutics Plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.